To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Fluorodeoxyglucose PET in… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Fluorodeoxyglucose PET in Neurology and Psychiatry

Journal article
Authors Michael Schöll
A. Damian
H. Engler
Published in PET Clinics
Volume 9
Issue 4
Pages 371-90
ISSN 1556-8598
Publication year 2014
Published at Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation
Pages 371-90
Language en
Links dx.doi.org/10.1016/j.cpet.2014.07.0...
Keywords Brain Diseases/*radionuclide imaging, *Fluorodeoxyglucose F18, Humans, Mental Disorders/*radionuclide imaging, *Positron-Emission Tomography, *Radiopharmaceuticals, Dementia, Fluorodeoxyglucose positron emission tomography, Neurology, Psychiatry, [(18)F]-Fluorodeoxyglucose
Subject categories Neurosciences

Abstract

PET imaging with the most widely available PET tracer, 2-deoxy-2-[(18)F]fluoro-d-glucose (FDG), is a powerful tool in the differential diagnosis of numerous neurologic and psychiatric disorders, particularly in early disease stages. It also plays an important role in the longitudinal evaluation of treatment effects and the depiction of disease courses. A selection of established and eligible application areas of FDG PET in neurology and psychiatry, such as different types of dementia, epilepsy, schizophrenia, and bipolar disorder, are reviewed in this article. A general methodology for clinical FDG PET examinations and typical diagnostic criteria and pitfalls are addressed.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?